.png)
.png)
Total amount raised
Latest funding date
Location
Bahram Bob Valamehr is the President and CEO of Fate Therapeutics, a company at the forefront of developing pluripotent stem cell technologies for therapeutic applications. With deep expertise in pluripotent cell strategies for creating off-the-shelf immunotherapeutics, his leadership reflects a strong commitment to advancing cancer immunotherapy and innovative cellular medicine.
Who is the CEO of Fate Therapeutics?
Bahram Bob Valamehr serves as the President and CEO of Fate Therapeutics, bringing extensive scientific and research leadership to the role. His work centers on developing pluripotent stem cell technologies for therapeutic applications, with a particular focus on pluripotent cell strategies for creating off-the-shelf immunotherapeutics in oncology.
His leadership at Fate Therapeutics is grounded in decades of hands-on research and development experience, driving the company's mission to deliver transformative cell-based cancer therapies.
Work History
Bahram Bob Valamehr's work history reflects a career dedicated to advancing cancer immunotherapy and cell-based research. Here is a summary of his professional journey:
- Fate Therapeutics - President and CEO, January 2025 – Present
- Fate Therapeutics - Chief Research & Development Officer, August 2018 – Present
- Fate Therapeutics - Vice President, Cancer Immunotherapy, January 2010 – Present
- Amgen - Associate, Research and Development, January 2000 – January 2004
Education History
Bahram Bob Valamehr's educational background is rooted in the life sciences. He studied at UCLA, where he focused on Molecular & Medical Pharmacology and Embryonic Stem Cell Research — a foundation that has directly informed his career developing pluripotent stem cell technologies and off-the-shelf immunotherapeutics.
When did Bahram Bob Valamehr join Fate Therapeutics?
Bahram Bob Valamehr assumed the role of President and CEO of Fate Therapeutics in January 2025. His appointment builds on a long tenure at the company, during which he led research and development efforts and helped shape Fate Therapeutics' scientific direction in pluripotent stem cell-based cancer immunotherapy.
